Intracell Medical Uk Limited

Intracell Medical Uk Ltd, based in Bromley, UK, is a small holding company with an active status, established six years ago in 2018. The company, with a single employee and £139,808 in assets, operates from a real address and is led by one director and owner. It regularly imports and exports optical and medical tools and devices, with 10 months of import activity and 4 months of export activity recorded.

The company’s website reveals a fascinating connection to IntraCellular Therapies, Inc., now part of Johnson & Johnson. This US-based pharmaceutical company focuses on developing treatments for neuropsychiatric, neurologic, and other disorders. The website details a pipeline of investigational compounds and approved products, including CAPLYTA, a medication for schizophrenia. The site emphasizes a mission to improve the lives of individuals with these conditions and highlights a diverse portfolio of research and development efforts. It’s clear that Intracell Medical Uk Ltd serves as a European arm, likely handling distribution, regulatory affairs, or other support functions for its parent company.

Financially, Intracell Medical Uk Ltd presents a mixed picture. While bank borrowings increased by 8%, cash reserves decreased by 23% to £15,000. Trade debtors saw a significant drop of 54%, which could indicate improved collection efforts or reduced sales. However, creditors also increased by 19%, suggesting higher short-term liabilities. Accumulated depreciation impairment on plant and machinery grew by 33%, reflecting ongoing investment in equipment. The company’s small size—meeting two of three criteria for a small company—allows for flexibility, but the decline in equity, from -£610 to £4,100, is notable. No auditor is mentioned, which is common for small, exempt companies.

Overall, Intracell Medical Uk Ltd appears to be a stable, albeit small, operation closely tied to the larger IntraCellular Therapies organization. The financial trends suggest a company managing its short-term obligations, but the decline in equity warrants monitoring. The company's role in supporting the parent company's European operations likely provides a degree of stability, but its long-term success depends on the continued growth and success of IntraCellular Therapies.

Registered in England/Wales under the registration number 11646451, with a registered address at BR1 1RJ, United Kingdom, Bromley, Kent, Leonard House First Floor, 5 - 7 Newman Road.

WARNING:The numbers have been rounded for simplicity and may be inaccurate.Please, refer to the latest financial report for verification.